<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hypertensive Emergencies</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="cardiology-systemic-hypertension-5.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 36.5%;"></div> <!-- Set percentage dynamically with static value for this chunk -->
                        </div>
                       <span class="progress-text">Lecture 19 of 52</span> <!-- Update text with static value for this chunk -->
                    </div>
                    <a href="cardiology-ischemic-heart-disease-5a.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">HYPERTENSIVE EMERGENCIES</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: introduction -->
                <section id="introduction" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Introduction</span>
                    </h2>
                    <div class="content-card">
                        <p>Joint National Committee (JNC-7) has introduced a new classification system for HTN.</p>
                        <h3 class="subsection-heading">Pre-hypertension</h3>
                        <ul>
                            <li>Systolic blood pressure (SBP) 120-139</li>
                            <li>Diastolic blood pressure (DBP) 80-89</li>
                        </ul>
                        <h3 class="subsection-heading">Stage I HTN</h3>
                        <ul>
                            <li>SBP 140-159</li>
                            <li>DBP 90-99</li>
                        </ul>
                        <h3 class="subsection-heading">Stage II HTN</h3>
                        <ul>
                            <li>SBP >160</li>
                            <li>DBP >100</li>
                        </ul>
                        <p>Hypertensive crises encompass a spectrum of clinical presentations where uncontrolled BPs lead to progressive or impending target organ dysfunction (TOD).</p>
                        <p>The clinical distinction between hypertensive emergencies and hypertensive urgencies depends on the presence of acute TOD and not on the absolute level of the BP.</p>
                        <h3 class="subsection-heading">Hypertensive emergency</h3>
                        <p>Hypertensive emergencies represent severe HTN with acute impairment of an organ system (eg central nervous system [CNS], cardiovascular, renal). In these conditions, the BP should be lowered aggressively over minutes to hours.</p>
                        <h3 class="subsection-heading">Hypertensive urgency</h3>
                        <p>Hypertensive urgency is defined as a severe elevation of BP, without evidence of progressive TOD. These patients require BP control over hours to days.</p>
                    </div>
                </section>
                <!-- END: introduction -->

                <!-- START: pathophysiology -->
                <section id="pathophysiology" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Pathophysiology</span>
                    </h2>
                    <div class="content-card">
                        <p>The pathophysiology of hypertensive emergencies is not well understood. However, an abrupt rise in vascular resistance seems to be a necessary initial step. The 3 major organ systems affected by high BP are the CNS, cardiovascular system, and renal system.</p>
                        <h3 class="subsection-heading">Central nervous system</h3>
                        <p>Cerebral autoregulation is the inherent ability of the cerebral vasculature to maintain a constant cerebral blood flow (CBF) despite changes in blood pressure. As mean arterial pressure (MAP) increases, the cerebral endothelium is disrupted and the blood-brain barrier can become interrupted. This leads to cerebral edema and microhemorrhages. Patients with chronic HTN can tolerate higher MAPs before they have disruption of their autoregulation system. However, such patients also have increased cerebrovascular resistance and are more prone to cerebral ischemia when flow decreases. Hypertensive encephalopathy is one of the clinical manifestations of cerebral edema and microhemorrhages seen with dysfunction of cerebral autoregulation.</p>
                        <h3 class="subsection-heading">Cardiovascular system</h3>
                        <p>HTN affects the structure and function of the coronary vasculature and left ventricle. HTN also activates the renin-angiotensin-aldosterone system, causing systemic vasculature constriction. This results in increasing myocardial oxygen demand by increasing the left ventricular wall tension and leads to left ventricular hypertrophy and coronary compression. During hypertensive emergencies, the left ventricle cannot overcome systemic vascular resistance. This leads to left ventricular failure and pulmonary edema or myocardial ischemia.</p>
                        <h3 class="subsection-heading">Renal system</h3>
                        <p>Chronic HTN causes pathologic changes to the small arteries of the kidney. The arteries develop endothelial dysfunction and impaired vasodilation, which alter renal autoregulation. When the renal autoregulatory system is disrupted, the intraglomerular pressure starts to vary directly with the systemic arterial pressure, thus offering no protection to the kidney during BP fluctuations. During a hypertensive crisis, this can lead to acute renal ischemia.</p>
                    </div>
                </section>
                <!-- END: pathophysiology -->

                <!-- START: demographics-morbidity -->
                <section id="demographics-morbidity" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Mortality/Morbidity, Sex, and Age</span>
                    </h2>
                    <div class="content-card">
                        <p><strong>Mortality/Morbidity:</strong> Death from both ischemic heart disease and stroke increase progressively as the BP increases. For every 20 mm Hg systolic or 10 mm diastolic increase in BP, the mortality rate from both ischemic heart disease and stroke doubles. The morbidity and mortality of hypertensive emergencies depend on the extent of TOD on presentation and the degree to which BP is controlled subsequently. With BP control and medication compliance, the 10-year survival rate of patients with hypertensive crises approaches 70%.</p>
                        <p><strong>Sex:</strong> Overall, the prevalence and incidence of HTN is slightly higher in men than in women. Hypertensive crises are two times more frequent in males than in females.</p>
                        <p><strong>Age:</strong> Hypertensive crises are more common among elderly persons.</p>
                    </div>
                </section>
                <!-- END: demographics-morbidity -->

                <!-- START: etiology -->
                <section id="etiology" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Etiology</span>
                    </h2>
                    <div class="content-card">
                        <p>The most common hypertensive emergency is a rapid unexplained rise in BP in a patient with chronic essential HTN.</p>
                        <p>Other causes:</p>
                        <h3 class="subsection-heading">A) Renal parenchymal disease</h3>
                        <ul>
                            <li>Chronic pyelonephritis.</li>
                            <li>Primary glomerulonephritis.</li>
                            <li>Tubulointerstitial nephritis (accounts for 80% of all secondary causes)</li>
                        </ul>
                        <h3 class="subsection-heading">B) Renovascular disease</h3>
                        <ul>
                            <li>Atherosclerotic disease</li>
                            <li>fibromuscular dysplasia</li>
                            <li>polyarteritis nodosa</li>
                        </ul>
                        <h3 class="subsection-heading">C) Systemic disorders with renal involvement</h3>
                        <ul>
                            <li>Systemic lupus erythematosus</li>
                            <li>Systemic sclerosis</li>
                            <li>Vasculitides</li>
                        </ul>
                        <h3 class="subsection-heading">D) Endocrine</h3>
                        <ul>
                            <li>Pheochromocytoma</li>
                            <li>Cushing syndrome</li>
                            <li>Primary hyperaldosteronism</li>
                        </ul>
                        <h3 class="subsection-heading">E) Drugs</h3>
                        <ul>
                            <li>Cocaine</li>
                            <li>Amphetamines</li>
                            <li>Cyclosporine</li>
                            <li>Clonidine withdrawal</li>
                            <li>Phencyclidine</li>
                            <li>diet pills, oral contraceptive pills</li>
                        </ul>
                        <h3 class="subsection-heading">F) Drug interactions</h3>
                        <ul>
                            <li>Monoamine oxidase inhibitors with tricyclic antidepressants</li>
                        </ul>
                        <h3 class="subsection-heading">G) CNS</h3>
                        <ul>
                            <li>CNS trauma</li>
                            <li>spinal cord disorders, such as Guillain-Barré syndrome</li>
                        </ul>
                        <h3 class="subsection-heading">Others</h3>
                        <ul>
                            <li>Preeclampsia/eclampsia</li>
                            <li>Postoperative hypertension</li>
                        </ul>
                    </div>
                </section>
                <!-- END: etiology -->

                <!-- START: clinical-evaluation -->
                <section id="clinical-evaluation" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Clinical Evaluation</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">History:</h3>
                        <p>The history should focus on:</p>
                        <ul>
                            <li>The presence of TOD</li>
                            <li>Circumstances surrounding the HTN</li>
                            <li>Any identifiable etiology.</li>
                        </ul>
                        <p>Assess whether specific symptoms suggesting TOD are present.</p>
                        <ul>
                            <li>Chest pain - Myocardial ischemia or infarction</li>
                            <li>Sharp retrosternal pain radiating to the back - Aortic Dissection</li>
                            <li>Dyspnea - Pulmonary edema, congestive heart failure</li>
                            <li>Neurologic symptoms - Seizures, visual disturbances, altered level of consciousness (hypertensive encephalopathy)</li>
                        </ul>
                        <p>Presence of previous TOD, particularly renal and cerebrovascular disease.</p>
                        <ul>
                            <li>Duration and severity of preexisting HTN</li>
                            <li>Degree of BP control</li>
                            <li>Medications
                                <ul>
                                    <li>Details of antihypertensive drug therapy and compliance</li>
                                    <li>Intake of over-the-counter preparations such as sympathomimetic agents</li>
                                    <li>Use of illicit drugs such as cocaine.</li>
                                </ul>
                            </li>
                            <li>Presence of comorbid conditions (eg, pheochromocytoma, Cushing disease, systemic lupus, renal disease)</li>
                        </ul>
                        <h3 class="subsection-heading">Physical:</h3>
                        <p>The physical examination should assess whether TOD is present.</p>
                        <ul>
                            <li><strong>Vitals</strong>
                                <ul>
                                    <li>BP should be measured in both the supine position and the standing position (assess volume depletion)</li>
                                    <li>BP should also be measured in both arms (a significant difference suggests an aortic dissection)</li>
                                </ul>
                            </li>
                            <li><strong>Fundoscopy</strong>
                                <ul>
                                    <li>The presence of new retinal hemorrhages, exudates, or papilledema suggests a hypertensive emergency.</li>
                                </ul>
                            </li>
                            <li><strong>Cardiovascular</strong>
                                <ul>
                                    <li>Jugular venous distension</li>
                                    <li>Crackles</li>
                                    <li>Peripheral edema</li>
                                </ul>
                            </li>
                            <li><strong>CNS</strong>
                                <ul>
                                    <li>Level of consciousness</li>
                                    <li>Visual fields</li>
                                    <li>Focal neurologic signs</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: clinical-evaluation -->

                <!-- START: differential-diagnosis -->
                <section id="differential-diagnosis" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Differential Diagnosis</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Acute Coronary Syndrome</li>
                            <li>Aneurysm, Abdominal</li>
                            <li>Congestive Heart Failure and Pulmonary Edema</li>
                            <li>Cushing Syndrome</li>
                            <li>Delirium Tremens</li>
                            <li>Dissection, Aortic</li>
                            <li>Encephalitis</li>
                            <li>Glomerulonephritis, Acute</li>
                            <li>Headache, Cluster Migraine Tension</li>
                            <li>Hyperthyroidism, Thyroid Storm, and Graves Disease</li>
                            <li>Myocardial Infarction</li>
                            <li>Pregnancy, Eclampsia Preeclampsia</li>
                            <li>Stroke, Hemorrhagic, Ischemia</li>
                            <li>Intracranial bleeds</li>
                        </ul>
                    </div>
                </section>
                <!-- END: differential-diagnosis -->

                <!-- START: investigations -->
                <section id="investigations" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Investigations</span>
                    </h2>
                    <div class="content-card">
                        <ol>
                            <li>Electrolytes, BUN, and creatinine levels to evaluate for renal impairment</li>
                            <li>CBC and smear to exclude microangiopathic anemia</li>
                            <li>Urinalysis (UA)
                                <ul>
                                    <li>Dipstick UA to detect hematuria or proteinuria (renal impairment)</li>
                                    <li>Microscopic UA to detect RBCs or RBC casts (renal impairment)</li>
                                </ul>
                            </li>
                            <li>Optional studies
                                <ul>
                                    <li>Toxicology screen</li>
                                    <li>Pregnancy test</li>
                                    <li>Endocrine testing</li>
                                </ul>
                            </li>
                        </ol>
                        <h3 class="subsection-heading">Imaging Studies:</h3>
                        <ol>
                            <li>Chest radiography is indicated in patients with chest pain or shortness of breath.
                                <ul>
                                    <li>Cardiac enlargement</li>
                                    <li>Pulmonary edema</li>
                                    <li>Widened mediastinum</li>
                                </ul>
                            </li>
                            <li>Head CT scans are indicated in patients with abnormal neurologic examinations.
                                <ul>
                                    <li>Intracranial bleeding</li>
                                    <li>Cerebral edema</li>
                                    <li>Cerebral infarction</li>
                                </ul>
                            </li>
                            <li>Electrocardiogram (ECG) to assess for evidence of myocardial ischemia or left ventricular hypertrophy</li>
                            <li>Chest CT scan, Tran esophageal echocardiography, or aortic angiogram is indicated in cases where aortic dissection is suspected.</li>
                        </ol>
                    </div>
                </section>
                <!-- END: investigations -->

                <!-- START: treatment -->
                <section id="treatment" class="content-section" aria-labelledby="section-heading-8">
                    <h2 id="section-heading-8" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Treatment</span>
                    </h2>
                    <div class="content-card">
                        <p>Patients with TOD usually require admission and rapid lowering of BP using intravenous (IV) medications. Suggested medication depends on the affected organ system. Even in cases of hypertensive emergencies, the BP should not be lowered to normal levels.</p>
                        <p>Rapid reduction in BP below the cerebral, renal, and/or coronary autoregulatory range will result in marked reduction in organ blood flow, possibly leading to ischemia and infarction. In general, the MAP should be lowered by no more than 20-25% in the first hour of treatment. If the patient remains stable, the BP should then be lowered to 160/100-110 in the next 2-6 hours. Please note the exceptions to this general rule listed below. These BP goals are best achieved by a continuous infusion of a short-acting, titratable, parenteral antihypertensive agent along with constant, intensive patient monitoring.</p>
                        <p>Rapid BP reduction is indicated in the following circumstances:</p>
                        <ol>
                            <li><strong>Acute myocardial ischemia</strong>
                                <ul>
                                    <li>Nitroglycerin IV</li>
                                    <li>Beta-blockers IV</li>
                                </ul>
                            </li>
                            <li><strong>CHF with pulmonary edema</strong>
                                <ul>
                                    <li>Nitroglycerin IV</li>
                                    <li>Lasix IV</li>
                                    <li>Nitroprusside IV</li>
                                </ul>
                            </li>
                            <li><strong>Acute aortic dissection:</strong>
                                <p>In cases of acute aortic dissection, the SBP should be decreased as rapidly as possible to a goal of 100-110 mm Hg or lower.</p>
                                <ul>
                                    <li>Labetalol IV</li>
                                    <li>Alternative - Nitroprusside IV with beta-blocker IV (eg, esmolol)</li>
                                </ul>
                            </li>
                            <li><strong>CVA:</strong>
                                <ul>
                                    <li>Evidence exists that patients who have acute strokes have better outcomes with higher BPs. Antihypertensive therapy is not routinely recommended for patients with acute stroke and HTN.</li>
                                    <li>Recent ischemic stroke and a SBP >220 mm Hg or a DBP >120-140 mm Hg can undergo cautious reduction of BP by about 10-15% (with IV nitroprusside or IV labetalol), if the patient is carefully monitored for neurologic deterioration related to the lower pressure.</li>
                                    <li>Intracranial hemorrhage (ICH): A precipitous fall in SBP may compromise cerebral perfusion and increase mortality. The controlled lowering of BP with IV nitroprusside or IV labetalol (in the absence of bradycardia) is currently recommended only when the SBP is >200 mm Hg or the DBP is >110.</li>
                                </ul>
                            </li>
                        </ol>
                        <h3 class="subsection-heading">Other Specific Conditions</h3>
                        <ul>
                            <li><strong>Monoamine oxidase (MAO)-tyramine interactions with acute hypertension</strong>
                                <ul>
                                    <li>Phentolamine IV</li>
                                </ul>
                            </li>
                            <li><strong>Pheochromocytoma</strong>
                                <ul>
                                    <li>Phentolamine IV</li>
                                    <li>Labetalol IV</li>
                                </ul>
                            </li>
                            <li><strong>Hypertensive encephalopathy</strong>
                                <ul>
                                    <li>Nitroprusside IV</li>
                                    <li>Labetalol IV</li>
                                    <li>Fenoldopam IV</li>
                                </ul>
                            </li>
                            <li><strong>Acute renal failure</strong>
                                <ul>
                                    <li>Fenoldopam IV</li>
                                    <li>Nicardipine IV</li>
                                    <li>Beta-blockers IV</li>
                                </ul>
                            </li>
                            <li><strong>Eclampsia</strong>
                                <ul>
                                    <li>Hydralazine IV</li>
                                    <li>Labetalol IV</li>
                                    <li>Magnesium IV</li>
                                </ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: treatment -->
                
                <!-- START: outpatient-management -->
                <section id="outpatient-management" class="content-section" aria-labelledby="section-heading-9">
                    <h2 id="section-heading-9" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Outpatient Management</span>
                    </h2>
                    <div class="content-card">
                        <p>The Joint National Committee on High Blood Pressure has published a series of recommendations for appropriate follow-up, assuming no TOD.</p>
                        <ul>
                            <li>Prehypertension (SBP 120-139, DBP 80-89): BP should be rechecked within 1 year.</li>
                            <li>Stage I HTN (SBP 140-159, DBP 90-99): BP should be rechecked within 2 months.</li>
                            <li>Stage II HTN: (SBP > 160 or DBP >100): Refer to source of care within 1 month.</li>
                            <li>If BP is >180/110, patient should be evaluated and treated within 1 week.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: outpatient-management -->

                <!-- START: complications -->
                <section id="complications" class="content-section" aria-labelledby="section-heading-10">
                    <h2 id="section-heading-10" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Complications:</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Congestive heart failure</li>
                            <li>Myocardial infarction</li>
                            <li>Renal failure</li>
                            <li>Retinopathy</li>
                            <li>Cerebrovascular accident</li>
                            <li>Hypertensive encephalopathy</li>
                            <li>Abrupt lowering of BP may result in inadequate cerebral or cardiac blood flow, leading to stroke or myocardial ischemia.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: complications -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="cardiology-systemic-hypertension-5.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 36.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 19 of 52</span>
                    </div>
                    <a href="cardiology-ischemic-heart-disease-5a.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>